Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms
Authors:
- Michael WillmannMWMichael Willmann
- Emir HadzijusufovicEHEmir Hadzijusufovic
- Olivier HermineOHOlivier Hermine
- Mauro DacastoMDMauro Dacasto
- Laura MarconatoLMLaura Marconato
- Karin BauerKBKarin Bauer
- Barbara PeterBPBarbara Peter
- Susanne GamperlSGSusanne Gamperl
- Gregor EisenwortGEGregor Eisenwort
- Erika Jensen‐JarolimEJErika Jensen‐Jarolim
- Mathias MüllerMMMathias Müller
- Michel ArockMAMichel Arock
Open Access
- 22 August 2018
- journal article
- review article
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 17 (1) , 1-10
Abstract
In humans, advanced mast cell (MC) neoplasms are rare malignancies with a poor prognosis. Only a few preclinical models are available, and current treatment options are limited. In dogs, MC neoplasms are the most frequent malignant skin tumours. Unlike low‐grade MC neoplasms, high‐grade MC disorders usually have a poor prognosis with short survival. In both species, neoplastic MCs display activating KIT mutations, which are considered to contribute to disease evolution. Therefore, tyrosine kinase inhibitors against KIT have been developed. Unfortunately, clinical responses are unpredictable and often transient, which remains a clinical challenge in both species. Therefore, current efforts focus on the development of new improved treatment strategies. The field of comparative oncology may assist in these efforts and accelerate human and canine research regarding diagnosis, prognostication, and novel therapies. In this article, we review the current status of comparative oncology approaches and perspectives in the field of MC neoplasms.Keywords
Funding Information
- Austrian Science Fund (P‐25937‐B13SFB, F4701‐B20SFB, F4704‐B20SFB, F6101SFB F6106)
This publication has 102 references indexed in Scilit:
- Mast cell leukemiaBlood, 2013
- NI‐1: a novel canine mastocytoma model for studying drug resistance and IgER‐dependent mast cell activationAllergy, 2012
- Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus ProposalInternational Archives of Allergy and Immunology, 2011
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KITPLOS ONE, 2009
- Ultrasound-Guided Cytology of Spleen and Liver: A Prognostic Tool in Canine Cutaneous Mast Cell TumorJournal of Veterinary Internal Medicine, 2009
- Mast cells and mastocytosisBlood, 2008
- Use of Kit Internal Tandem Duplications to Establish Mast Cell Tumor Clonality in 2 DogsJournal of Veterinary Internal Medicine, 2004
- Response to Interferon Alfa-2b in a Patient with Systemic MastocytosisNew England Journal of Medicine, 1992
- Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and MastocytosisNew England Journal of Medicine, 1987
- Mast Cell Leukemia: Report of a Case and Review of the LiteratureMayo Clinic Proceedings, 1986